Hepatoprotective Activities of Triphala and Its Constituents

Rasnna Gupta¹, Ankit Gupta², *Ram Lakhan Singh¹

1. Nutraceutical Laboratory, Department of Biochemistry, Dr. Ram Manohar Lohia Avadh University, Faizabad-224001, Uttar Pradesh, India.
2. National Institute of Allergy and Infectious Disease, National Institute of Health, 12735 Twinbrook Parkway, Rockville, MD-20852-8132, USA.

ABSTRACT
Liver is a vital organ which plays major role in metabolism and excretion of xenobiotics from the body. Liver injury or its dysfunction is a major health problem that challenges not only health care professionals but also the pharmaceutical industry and drug regulatory agencies. Liver cell injury caused by various toxic chemicals, certain chemotherapeutic agents, carbon tetrachloride, excessive alcohol, overloaded iron is well-studied. Some synthetic compounds such as antimicrobials, anticonvulsants, corticosteroids, NSAIDs and analgesic etc. are currently available as hepatoprotective agents. However, such compounds are not totally safe and exert several side effect and disadvantages. In view of severe adverse side effects of synthetic agents, there is growing need to develop more valuable and protected drugs which may be of therapeutic benefits to patients. Hence herbal drugs have become increasingly popular and their use is increasing day by day. A number of herbal preparations are available in the market. Triphala is one of the age old most commonly used polyherbal formulations with known hepatoprotective activities in Indian system of medicine mainly in Ayurveda. This is well known phytomedicine, a combination of three medicinal plants with Phyllanthus emblica (Amlaki, Phyllanthaceae), Terminalia chebula (Haritaki, Combretaceae) & Terminalia bellirica (Baheda, Combretaceae). Present review focuses on mechanism of hepatotoxicity and various scientifically tested hepatoperotective properties of formulation Triphala and its constituents.

Keywords: Hepatoprotection, hepatotoxicity, Phyllanthus emblica, Terminalia bellerica, Terminalia chebula, triphala

Received 21 Oct 2014    Received in revised form 19 Dec 2014    Accepted 22 Dec 2014

*Address for correspondence:
Dr. Ram Lakhan Singh,
Professor and Head
Department of Biochemistry, Dr. Ram Manohar Lohia Avadh University, Faizabad – 224001,
Uttar Pradesh, India.
E-mail: drrlsingh@rediffmail.com

INTRODUCTION
Liver is the key organ for detoxification of toxic substances and disposition of endogenous substances. It is continuously and widely exposed to toxins and chemotherapeutic agents that lead to impairment of its function. Chronic Liver diseases stand as one of the foremost health troubles worldwide. Liver disease is one of the major causes of death [1]. According to the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC), chronic liver disease and cirrhosis is the 12th leading cause of death, claiming 30,000 lives annually in the United States [2]. Liver undergoes progressive changes during injury (Figure 1). Liver is involved in wide range of body functions including protein synthesis, production of biochemicals necessary for digestion and synthesis as well as metabolism of complex molecules. Additionally, the toxins absorbed from the intestinal tract go first to the liver resulting in a variety of liver complaints. Many factors are responsible for liver injuries (Figure 2). Oxidative stress, which results due to imbalance between the antioxidant defense system and the formation of
reactive oxygen species (ROS), may induce damage to hepatocellular biomolecules such as proteins, carbohydrates, lipids, RNA and DNA through oxidative modification and contributing to the pathogenesis of human diseases [3]. Some synthetic compounds are currently available as hepatoprotective agents (Table 1). However, such compounds may exert several side effects and disadvantages. In view of severe adverse side effects of synthetic agents, there is growing focus to develop more valuable and protected drugs which may raise the therapeutic benefits for patients. A large number of medicinal plants have been tested and found to contain active principles with therapeutic properties against hepatotoxicity. Plants contain a variety of chemical constituents like phenols, carotenoids, glycosides, flavonoids, organic acids, lipids and alkaloids which showed hepatoprotective activity. Medicinal plants containing phytochemicals with antioxidant potential have strong protective effect against hepatotoxicity [4]. A number of herbal formulations from plant origin are evaluated for their possible antioxidant and hepatoprotective effects against chemically induced liver damage. A large number of plants and their formulations have been claimed to have hepatoprotective activity so the development of plant based hepatoprotective drugs have been given importance in the global market (Table 2). Herbal remedies are very promising and valuable alternative options for treatment of liver complaints.

**Figure 1.** Progressive changes in anatomy of Liver during hepatotoxicity

**Figure 2.** Major cause of chronic Liver diseases

Hepatitis C virus (HCV), Non-alcoholic steatohepatitis (NASH), Autoimmune hepatitis (AIH), Primary sclerosing cholangitis (PSC), Primary biliary cirrhosis (PBC), Hepatitis C virus (HBV)
### Table 1: Synthetic drugs causing liver injury at higher concentrations

<table>
<thead>
<tr>
<th>Nature of drugs</th>
<th>Name of Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anesthetics</td>
<td>Desflurane, Enflurane, Halothane, Hyoscine, Isoflurane, Methohexitol</td>
</tr>
<tr>
<td>Antimicrobials</td>
<td>Bacitracine, Dapsone, Isoniazid, Ketoconazole, Nalidixic acid, Penicillin, Pyrazinamide, Rifampicin, Sulfonamides, Trovafloxacin, Vancomycin</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Carbamazepine, Felbamate, Halothane, Isoflurane, Nimetazepam, Nitrazepam, Phenytoin, Temazepam, Valproic acid</td>
</tr>
<tr>
<td>NSAIDs and analgesic</td>
<td>Bromfenac, Diclofenac, Etodolac, Flurbiprofen, Ibuprofen, Indome thacin, Paracetamol, Piroxicam Oxaprozin, Sulindac</td>
</tr>
<tr>
<td>Miscellaneous agents</td>
<td>Disulfiram, Flutamide, Labealol, Nefazodone, Nicotinic acid, Pemoline, Propylthiouracil, Tolcapone, Troglitazone</td>
</tr>
</tbody>
</table>

### Table 2: Common hepatoprotective polyherbal formulations and their plant sources

<table>
<thead>
<tr>
<th>S.N.</th>
<th>Formulation Name (manufacture)</th>
<th>Reported Plant sources and (their parts used)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Acilvan (Acis Laboratories, Kanpur)</td>
<td>Achillea millefoliiven (flower and leaf), Boerhavia diffusa (leaf), Capparis spinosa (fruit), Casearia esculenta (root), Cassia occidentalis (whole plant), Chichorium intybus (whole plant), Eclipta alba (leaf), Ocimum sanctum (whole plant), Picrorrhiza kurroa (root), Solarum nigrum (fruit), Tamarix gallica (flower), Terminalia arjuna (fruit), Tinospora cordifolia (stem).</td>
</tr>
<tr>
<td>2</td>
<td>Adliv (Abala Drug House, Kolkata)</td>
<td>Aloe barbadensis (leaf), Andropogon muricatus (leaf), Asteracantha longifolia (leaf), Centella asiatica (leaf), Carum copticum (seed), Cassia angustifolia (leaf), Holarrhena antidysenterica (seed and bark), Solarum xanthocarpum (fruit).</td>
</tr>
<tr>
<td>3</td>
<td>Amlycure (Aimil Pharmaceuticals Pvt. Ltd., Kolkata)</td>
<td>Achillea millefoliiven (flower and leaf), Aloe barbadensi (leaf), Berberis lyceum (root), Cassia obtusifolia (leaf), Cassytha filliformia (leaf), Chichorium intybus (root), Eclipta alba (leaf), Fumaria officinalis (seed), Helleborus niger (flower), Ipomoea turpethum (root), Ocimum sanctum (seed), Panicum milliari (seed), Solarum nigrui (fruit), Tephrosia purpurea (root), Terminalia belerica (seed).</td>
</tr>
<tr>
<td>4</td>
<td>Biligen (Standard Pharmaceuticals, Kolkata)</td>
<td>Ipomoea turpethum (stem and leaf), Swertia chirata (seed), Trachyspermum ammi (seed), Trigonella foenumgraecum (seed).</td>
</tr>
<tr>
<td>5</td>
<td>Hepa-10 (Jupiter Pharmaceuticals Pvt Ltd., Kolkata)</td>
<td>Aloe barbadensis (leaf), Andrographis paniculata (leaf and root), Apium graveolens (stem bark), Eclipta alba (whole plant), Fumaria officinalis (leaf), Luffa echinata (fruit), Pycnostis ajowan (seed), Solarum nigrum (fruit).</td>
</tr>
<tr>
<td>6</td>
<td>HepeX The Anglo French Drug Co. (Eastern Ltd., Mumbai)</td>
<td>Boerhavaia diffusa (leaf), Phyllanthus Emblica (fruit), Phyllanthus niruri (fruit).</td>
</tr>
<tr>
<td>7</td>
<td>Hipex (H.V. Pharmaceuticals, Rajkot, Gujarat)</td>
<td>Boerhavaia diffusa (leaf), Cassia occidentalis (leaf and seed), Chichorium intybus (root), Embelia ribes (leaf and root bark), Solarum nigrum (fruit), Terminalia chebula (fruit).</td>
</tr>
<tr>
<td>8</td>
<td>Kalmegh (Bengal Chemicals Pharmaceuticals Pvt. Ltd., Kolkata)</td>
<td>Andrographis paniculata (leaf and stem), Apium graveolens (seed), Carum copticum (fruit).</td>
</tr>
<tr>
<td>No.</td>
<td>Product Name</td>
<td>Ingredients</td>
</tr>
<tr>
<td>-----</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>9</td>
<td>Liv-52 (Himalaya Drug Co., Mumbai)</td>
<td>Achillea millefolium (leaf and flower), Andrographis paniculata (leaf and root), Boerhavia diffusa (root), Capparis spinosa (bulb and fruit), Cassia occidentalis (seed), Cinchonia intybus (root), Eclipta alba (seed), Fumaria officinalis (flower), Phyllanthus emblica (fruit), Phyllanthus niruri (fruit), Solanum nigrum (fruit), Tamarix gallica (leaf and bark), Terminalia arjuna (bark), Terminalia chebula (fruit), Tinospora cordifolia (stem).</td>
</tr>
<tr>
<td>10</td>
<td>Liv-77 (Gobe Pharmaceuticals Pvt Ltd., Kolkata)</td>
<td>Berberis lyceum (leaf and fruit), Boerhavia diffusa (leaf and seed), Chichorium intybus (root), Eclipta alba (seed), Hemidesmus indicus (root), Prunus domestica (fruit), Tinospora cordifolia (stem).</td>
</tr>
<tr>
<td>11</td>
<td>Liva-16 (Madona Pharmaceutical Research, Kolkata)</td>
<td>Piper nigrum (unripe fruit), Oldenlandia corymbosa (root), Solanum nigrum (fruit), Solanum xanthocarpum (fruit), Tinospora cordifolia (stem).</td>
</tr>
<tr>
<td>12</td>
<td>Livarin (Pathiala Ayurvedic Pharm., Sirhind)</td>
<td>Picrorrhiza kurroa (root), Solanum nigrum (fruit), Tecoma undulate (leaf).</td>
</tr>
<tr>
<td>13</td>
<td>Livatone (East India Pharmaceuticals Pvt Ltd., Kolkata)</td>
<td>Holarrhena antidysenterica (bark), Andrographis paniculata (leaf and root), Apium graveolens (seed), Asteracantha longifolia (seed), Trigonella foenumgraecum (seed).</td>
</tr>
<tr>
<td>14</td>
<td>Livergen (Standard Pharmaceutical, Kolkata)</td>
<td>Andrographis paniculata (root), Apium graveolens (seed), Asteracantha longifolia (seed), Cassia angustifolia (fruit), Trachyspermum ammi (seed), Trigonella foenumgraecum (seed).</td>
</tr>
<tr>
<td>15</td>
<td>Livex (Bhartiya aushadhi Nirmanshala, Rajkot, Gujarat)</td>
<td>Achillea millefoliiven (flower and leaf), Aconitum heterophyllum (root), Cassia occidentalis (leaf), Embelia ribes (fruit), Solanum nigrum (seed), Swertia chirata (root), Tamarix gallica (leaf).</td>
</tr>
<tr>
<td>16</td>
<td>Livin (Araya Aushadhi Pharmaceuticals Works, Indore)</td>
<td>Acorus calamus (root), Andrographis paniculata (leaf), Aphnamixis polystachya (stem bark), Boerhavia diffusa (root), Cassia sophera (leaf), Citrullus colocynthis (root), Eclipta alba (seed), Ipomoea turpethum (root), Jatrohrrhiza palmate (root), Latseha chinesis (bark), Lawsonia inermis (leaf), Ocimum sanctum (leaf), Plumbago zeylanica (root), Salvadora persica (bark), Tephrosia purpurea (stem), Terminalia chebula (fruit), Tinospora cordifolia (whole plant), Trachyspermum ammi (seed).</td>
</tr>
<tr>
<td>17</td>
<td>Livodin (Madona Pharmaceutical Research, Kolkata)</td>
<td>Aloe barbadensis (leaf), Andrographis paniculata (leaf), Aphnamixis polystachya (leaf), Asteracantha longifolia (seed), Carum copticum (seed), Cassia angustifolia (leaf), Embelia ribes (seed), Holarrhena antidysenterica (seed), Piper nigrum (leaf), Solanum xanthocarpum (fruit), Tinospora cordifolia (stem).</td>
</tr>
<tr>
<td>18</td>
<td>Livosin (Jupiter Pharmaceuticals Pvt Ltd., Kolkata)</td>
<td>Andrographis paniculata (leaf), Avena sativa (seed), Carica papaya (seed), Cassia angustifolia (leaf), Embelia ribes (seed), Holarrhena antidysenterica (seed), Mentha viridis (leaf), Phyllanthus Emblica (fruit), Solanum nigrum (seed), Terminalia arjuna (fruit), Terminalia belerica (fruit).</td>
</tr>
<tr>
<td>19</td>
<td>Livomyon (Charak Pharmaceuticals (India) Pvt. Ltd., Umbaraon, Gujarat)</td>
<td>Aphnamixis polystachya (bark), Capparis spinosa (root bark), Cassia occidentalis (leaf), Embelia ribes (seed), Fumaria officinalis (root), Ipomoea turpethum (root bark), Plumbago zeylanica (root), Swertia decussate (whole plant), Tephrosia purpurea (whole plant), Tinospora cordifolia (whole plant).</td>
</tr>
</tbody>
</table>
Table 3

<table>
<thead>
<tr>
<th>No</th>
<th>Company Name</th>
<th>Herbal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Livomycin (Charak Pharmaceuticals (India) Pvt. Ltd., Umbergaon, Gujarat)</td>
<td><em>Boerrhaavia diffusa</em> (root).</td>
</tr>
<tr>
<td>23</td>
<td>Livotone (Gambers Laboratories, Mumbai)</td>
<td><em>Andrographis paniculata</em> (leaf), <em>Aipium graveolens</em> (seed), <em>Asteracantha longifolia</em> (seed), <em>Holarrhena antidysentrica</em> (seed).</td>
</tr>
</tbody>
</table>

Triphala is an Ayurvedic herbal *Rasayana* formula consisting of equal parts of three plants Amliaki, *Phyllanthus emblica* (syn. *Emblica officinalis*) of Phyllanthaceae family, Haritaki (*Terminalia chebula*) & Baheda (*Terminalia bellirica*) both belonging to Combretaceae family. Triphala is believed to be a well-known phytomedicine that promotes health, immunity, and longevity. All three constituents of Triphala are used in preparation of many hepatoprotective formulations (Table 3). Available research papers and review articles on the subject give scanty information especially on hepatoprotective activities of Triphala and its constituents which
does not serve the purpose of researchers or pharmaceutical industry. Hence there is need of a review which focuses solely on its hepatoprotective activities. Present review focuses on the scientifically tested hepatoprotective properties of Triphala and its constituents.

### Table 3: Formulations with constituents of Triphala

<table>
<thead>
<tr>
<th>Plant</th>
<th>Family</th>
<th>Parts used</th>
<th>Name of formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Phyllanthus Emblica</em></td>
<td>Phyllanthaceae</td>
<td>Fruit and leaves</td>
<td>Hepex, Livertone, Livol, Vinliv, Livosin, Neolive 100</td>
</tr>
<tr>
<td><em>Terminalia Bellerica</em></td>
<td>Combretaceae</td>
<td>fruit</td>
<td>Livol, Livosin, Amlycure Hipex, Livol, Livomap, Livertone, Livin, Livokin, Tefroli</td>
</tr>
<tr>
<td><em>Terminalia Chebula</em></td>
<td>Combretaceae</td>
<td>Fruit and leaves</td>
<td>Hipex, Livol, Livomap, Livertone, Livin, Livokin, Tefroli</td>
</tr>
</tbody>
</table>

### Mechanisms of hepatotoxicity

The physiological mechanism of hepatotoxicity includes both hepatocellular and extracellular pathways

#### a. Paracetamol mediated

N-acetyl-p-benzoquinone imine is a bioactive toxic electrophile of paracetamol, which binds covalently to lipids, and leads to their peroxidation. It also binds proteins through intermediate formation of ROS and reactive nitrogen species (RNS) such as superoxide anion, hydroxyl radical and hydrogen peroxide, nitro oxide and peroxynitrite [5]. ROS play an important role in liver fibrogenesis throughout increasing platelet-derived growth factor which leads to hepatocellular carcinomas, chronic inflammation associated with severe oxidative stress [5].

#### b. Ethanol mediated

Excessive alcohol consumption can result in to acute and chronic liver diseases because 80% of ingested alcohol is metabolized in the liver. During metabolism of ethanol to acetaldehyde in the body, a state of oxidative stress is created by excessive ROS generation, which plays a vital role in development of alcoholic liver diseases. Ethanol-activated cytochrome P4502E1 dependent cell destruction is apoptotic in nature which is associated with activation of caspase 3 and induces cell death [6].

#### c. Halogen mediated

Fluoride is a ubiquitous chemical compound. Its overexposure induces formation of free radicals [7] and further leads to histopathological changes in liver involving necrosis, infiltration of leucocytes, swelling of kupffer cells, extensive vacuolization, ultrastructural alteration in hepatocytes and increased apoptosis in animals and humans [8-10]. 2-Acetylaminofluorene (2-AAF) is a carcinogenic and mutagenic derivative of fluorene which induces tumor formation in liver at high exposure levels.

Some chloride derivatives like carbon tetra chloride (CCl₄) and 1,2-dimethylhydrazinedihydrochloride (DMH) exposure results in hepatotoxicity. CCl₄ has direct destructive effect on membranes of the hepatocyte and on consequent interface with cellular metabolism and transport. It damages the membrane of the hepatocyte causing leakage of enzymes present in the cell. This results in elevation of plasma tramaninas [11,12]. CCl₄ is metabolized in liver by cytochrome P450 dependent electron transport chain system yielding trichloromethyl radical (CCl₃O₂⁺) that under aerobic condition rapidly gets converted to its peroxyl radical. These radicals bind directly to lipids and proteins through covalent bonds and also interact with membrane phospholipids leading to promotion of LPO [13]. CCl₄ has been shown to
activate Kupffer cells by increasing intracellular Ca\(^{2+}\) concentration, causing release of harmful cytokines that contribute to cause death of hepatocytes and oxidative stress [14].

d. Anti-tuberculosis drugs mediated

Anti-tuberculosis (anti-TB) drug induced liver injury is a leading cause of liver failure in India and many developed countries. Some most commonly used anti-TB drugs are isoniazid, rifampicin and pyrazinamide. Isoniazid undergoes acetylation by N-acetyl transferase 2 (NAT-2). Acetyl-isoniazid is metabolized mainly to mono-acetyl hydrazine (MAH) and to the nontoxic diacetyl hydrazine. Reactive metabolites of MAH are probably toxic to tissues through free radical generation [15]. Isoniazid inhibits the activity of several cytochrome P450 2E and 2C enzymes, potentially increasing the plasma concentrations of other potentially hepatotoxic drugs, such as phenytoin and carbamazepine [16,18]. Rifampicin appears to enhance a metabolic hepatocellular characteristic reaction in patients getting isoniazid, perhaps by supporting the formation of toxic isoniazid metabolites [19,20]. Rifampicin occasionally can cause hepatocellular injury and potentiate hepatotoxic action of other anti-TB medications [21,22]. Pyrazinamide, a nicotinic acid derivative alters nicotinamide acetyl dehydrogenase levels in rat liver [23], which might results in generation of free radical species.

e. Iron mediated

Extreme iron deposition increases liver injury which is induced by iron-generated oxyradicals and peroxidation of lipid membranes. LPO results in damage of hepatocellular organelles such as mitochondria and lysosomes, which is thought to contribute to hepatocyte necrosis and apoptosis [24], inflammation [25] and ultimately lead to the development of hepatic fibrogenesis [26,27] and even to cancer [28]. Some synthetic compounds such as deferoxamine, deferiprone and deferasirox are currently used as iron chelating agents. However, such compounds are inadequate and exert several side effect and disadvantages [29,30]. In view of severe adverse side effects of synthetic agents, there is growing focus to develop more valuable and protected drugs [31,32] which may raise the therapeutic benefits for patients.

f. D-Galactosamine mediated

D-galactosamine (D-GalN) is used as a model hepatotoxin to stimulate experimental liver injury [33,34]. D-GalN induces acute liver injury in mice and has been used to mimic the sequences of events in viral hepatitis [35]. Ingestion of D-GalN depletes several uracil nucleotides and results in formation of uridine-diphosphogalactosamine (UDP-GalN) [36]. High accumulation of UDP-GalN contributes to disturbance in protein metabolism [37,38]. It is reported that D-GalN may cause loss of the intracellular calcium homeostasis, leading to cell membrane damage [33,39]. It results in hepatocyte necrosis and parenchymal inflammation and also causes imbalance in energy metabolism of hepatic cells [40].

g. Neutrophile mediated

Neutrophiles [41] and liver macrophages [42] derived ROS can cause necrotic cell injury by opening the membrane permeability transition pore and collapse of the mitochondrial membrane potential [43].

h. Nitric oxide mediated

Hepatocytes express inducible nitric oxide synthase (iNOS). Administration of paracetamol at high doses induce the expression of iNOS in rat hepatocytes [44]. An increase in serum nitrate and nitrite result in increased level of serum marker alanine transferase (ALT) in wild type mice. Based on liver biopsy specimens, ALT elevations in asymptomatic patients have also been connected with fatty liver [45]. In fact, nonalcoholic steatosis has been mentioned as a very common cause of chronic ALT elevations in the general population [46].
i. Non-steroidal anti-inflammatory drugs mediated

Non-steroidal anti-inflammatory drugs (NSAIDs) are responsible for roughly 10% of the total cases of drug-induced hepatotoxicity. Aspirin, Nimesulide, Diclofenac and Ibuprofen are commonly used NSAIDs. As epidemiological risk is very low, 10 in 100 000, but at high dose it can be serious and can cause diagnostic confusion [47]. Nearly all of the NSAIDs have been implicated in causing liver injury which tends to be hepatocellular in nature [48]. Several NSAIDs have been withdrawn from clinical use because of associated hepatotoxicity [49]. The new more selective COX-2 inhibitors (e.g. celecoxib, rofecoxib, nimesulide) are also associated with hepatotoxicity [50]. Aspirin may uncouple mitochondrial respiration [51] and induces the permeability transition pore [52,53].

Inhibition of mitochondrial β-oxidation of fatty acid causes microvesicular steatosis [54]. Administration of some drugs such as aminodarone, perhexiline concentrates into mitochondria to cause LPO leading to nonalcoholic steatohepatitis (NASH) and ultimately to liver cell death. Both LPO and ROS-induced cytokine (TGF-β, TNF-α, IL-8) release may contribute to the development of NASH [55]. Mitochondrial apoptosis (MA) is another mechanism of hepatotoxicity caused by opening of permeability transition (PT) pores in the mitochondrial inner membrane. PT pore opening in all mitochondria of a cell causes ATP depletion, which prevents apoptosis (an energy-requiring process) and causes necrosis [56]. In mitochondria undergoing the MPT, however, matrix swelling and outer membrane rupture causes release of mitochondrial cytochrome c which activates caspases in the cytosol to cause apoptosis [57,58] (Figure 3). Mitochondrial permeability transition (MPT) in the mitochondrial inner membrane is also the major cause of cytolytic hepatitis [59]. Reactive metabolites may cause DNA damage and overexpression of p53 and Bax, as well as glutathione depletion, protein thiol oxidation, and increased cytosolic Ca\(^{2+}\), disulfide formation, and increased mitochondrial Ca\(^{2+}\) homeostasis, all promote MPT and cell death [60].

![Figure 3. ROS/Reactive metabolites and overexpression of Bax and p53 inhibits Bcl-2 protein (an anti-apoptotic protein) and induces apoptosis.](image)

j. tert-Butyl hydroperoxide (t-BHP) mediated

t-BHP exposure to hepatocytes exert severe damage, lower reduced glutathione to total glutathione ratio and results in increased formation of ROS and decrease in mitochondrial membrane potential. t-BHP is
metabolized by cytochrome P450, leading to production of peroxyl and alkoxyl radicals [61]. These radicals initiate LPO of membrane phospholipids with subsequent alterations to membrane fluidity and permeability. Other pathway of its metabolism employs glutathione peroxidase (GPx). t-BHP is detoxified to tert-butanol and glutathione (GSH) is depleted by oxidation to its disulphide form (GSSG) [62]. LPO, depletion of GSH and the onset of mitochondrial MPT are general mechanisms involved in cell injury caused by oxidative stress.

**Hepatoprotective activities of Triphala: a polyherbal formulation:**

Triphala (equi proportion of Baheda, Harad and Amla in 1:1:1 ratio) is well known phytomedicine as accounted in the Ayurveda. It is widely accepted herbal formulation because of its exclusive capability to gently cleansing and detoxifying the body while at the same time strengthening and nourishing it due to rich source of antioxidants. As per the information available in Ayurvedic literature, Triphala may be used for the treatment of fever, cough, diarrhea, dysentery, skin disease, liver diseases [63] and gastrointestinal tract diseases [64,65]. Triphala is confirmed to have antiviral and antibacterial effects [65]. It is also recommended in myocardial injury, cancer etc. [66,67]. Its antidiabetic [68], antimutagenic [69], pergative [70], radioprotective [71] and cholesterol lowering [72] activities have been reported. It is not only relaxing and regulatory for digestion, but also regulates bowel movement, strengthens and revitalizes body tissues, increases the body's ability to absorb nutrients, boost life energies and is an entirely natural antioxidant.

*Charaka Samhita*, an 8th century text on Ayurvedic medicine, describes Triphala churna as rejuvenating medicament that can be used alone or in formulation. Charaka, the author of *Charaka Samhita*, states that “by using Triphala constantly for one year, one can live for a hundred years, free from ageing and diseases” [73]. Because it works slowly and lightly it can be taken over long periods of time without a problem.

**a. Protective effect of Triphala against paracetamol**

The activities of serum enzymes ALT, aspartate amino transaminase (AST), alkaline phosphatase (ALP) were extensively increased in paracetamol treated group as compared to control group. Aqueous extract of Triphala at 100 mg/kg body weight (b.w.) inhibits paracetamol at 900 mg/kg b.w. induced hepatotoxicity in mice as indicated by the decrease in serum AST, ALP, inflammatory mediator TNF-α and liver LPO [74]. Simultaneously, paracetamol administration increases malondialdehyde level (an end product of LPO) whereas levels of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), GPx, glutathione reductase (GR), glutathione S-transferase (GST) and GSH were found to be decreased when compared with the control group. Aqueous extract of Triphala reversed the above changes by regulating the MDA level and antioxidant enzymes to nearly that of normal levels. Thus Triphala inhibits LPO and prevents oxidative stress [74].

**b. Protective effect of Triphala against Ethanol**

The aqueous and methanolic extract of Triphala exerts significant protection against ethanol-induced toxicity by its ability to improve the oxidative stress enzyme system through free radical scavenging activity, which enhances levels of antioxidant defense system. The study also showed that methanolic extract of Triphala at dose of 100 mg/kg b.w. had greater effect than aqueous extract at the same dose level. Therefore, methanolic extract appears to be more useful in the attenuation of ethanol induced oxidation and showed more prominent effect than aqueous extract. Both the extracts showed significant activity against liver damage when compared with standard drug silymarin [75].
c. Protective effect of Triphala against 1,2-dimethylhydrazinedihydrochloride (DMH)
DMH treatment causes liver necrosis through changes in the liver microsomal proteins, which reversed back to the normal patterns after treatment with Triphala. It prevents the liver necrosis in DMH treated mice at oral dose of 3 mg/kg b.w. Administration of DMH significantly increased level of serum enzymes ALT, AST and ALP. However, Triphala administration to DMH treated mice led to decreased activation of above enzymes in serum showing the stabilization of plasma membranes as well as the repair of hepatic tissue damage due to DMH exposure. Triphala simultaneously increased the level of antioxidant enzyme GSH and the activity of GST suggesting that it prevents peroxidative damage and also diverts the active metabolites of DMH from their interaction with critical cellular biomolecules which could be responsible for its protective action against DMH [76].

d. Protective effect of Triphala against D-galactosamine (D-GalN)
It is reported that D-GalN induced hepatic damage resulted in a significant increase in the levels of ALT, AST, ALP, bilirubin, LPO (MDA level) and TNF-α with a decrease in the levels of antioxidant enzymes such as SOD, CAT, GPx, GR, GST and GSH which attained normal levels after the treatment with aqueous Triphala extract at 1000 mg/kg b.w. [77]. Pretreatment of Triphala inhibited LPO, suggesting that Triphala may exert a stabilizing action on liver cell membranes [77].

Hepatoprotective activities of Phyllanthus emblica:
P. emblica Linn, or Emblica officinalis Gaertn commonly known as Indian gooseberry or Amla, belongs to family Euphorbiaceae. The plant species, which was originally native to India, is today found growing in Pakistan, Uzbekistan, Sri Lanka, South-East Asia, China, and Malaysia [78,79]. It is well-known that all parts of amla plant are used to treat a range of diseases, but the most significant is the fruit. Fruit is used either alone or in combination with other plants to treat many ailments such as common cold, fever, peptic ulcer, dyspepsia, and it is also used as a digestive aid. Amla is one of the richest source of vitamin C (478.56 mg/100ml) having more vitamin C than orange and lemon. It contains many active phytochemicals like gallic acid, ellagic acid, emblicanin A, emblicanin B, puniglucuronin and pedunculagin [78] and flavonoids [79,80] (Table 4).

Pharmacological research on amla revealed its analgesic [81], anti-tussive [82], anti-atherogenic [83], adaptogenic [84], cardioprotective [85], hepatoprotective [86], gastroprotective [87], nephroprotective [88], neuroprotective [89] and anticancer [90] properties. Amla is also reported to possess chemopreventive [91], radioprotective [92], wound healing [93], immunomodulatory [94], free radical scavenging [95], antioxidant [96], antidiabetic [97], anti-diarrheal [98] and anti-viral [99] properties. These properties are effective in the prevention and treatment of various diseases like cancer, peptic ulcer, atherosclerosis, diabetes, anemia, liver, heart diseases and various other disorders.

a. Protective effect of P. emblica against paracetamol
Pretreatment of rats with P. emblica fruits extract at oral doses of 100-200 mg/kg b.w. 4 hrs before paracetamol administration, lowered the extent of hepatotoxicity. It has been reported that tannins and flavanoids present in P. emblica are responsible for their dominant antioxidant and hepatoprotective activities [100,101]. A polyherbal formulation with P. acidus (30 g), Moringa oleifera (40 g) and P. emblica (30 g) showed activity against paracetamol induced liver toxicity in albino rats [102]. Ethanolic extract of P. emblica leaf was more effective against hepatotoxicity [102].

b. Protective effect of P. emblica against ethanol
Alcohol administration in rats showed a significant oxidative stress and ROS
mediated toxicity. *P. emblica* fruit extract was investigated on ethanol induced rat hepatic injury. Pretreatment of rats with *P. emblica* at oral dose of 25, 50 and 75 mg/kg b.w. or silymarin (a reference hepatoprotective agent) at 5 mg/kg, 4 h before ethanol treatment, lowered the ethanol induced levels of AST, ALT and interleukine-1 (IL-1). The 75 mg/kg b.w. *P. emblica* dose showed best results similar to silymarin. Histopathological studies confirmed the beneficial roles of *P. emblica* and silymarin against ethanol induced liver injury in rats [103]. Administration of *P. emblica* fruit extract at a dose of 250 mg/kg b.w. per day to alcoholic rats offers protection by simultaneously lowering the carbonyl content and LPO, and elevating antioxidant enzyme activities [104].

c. Protective effect of *P. emblica* against CCl₄
A single dose of CCl₄ (1 ml/kg b.w.) elevated the levels of AST, lactate dehydrogenase (LDH), GST and depleted the levels of GSH, glutathione peroxidase (GPx) and glutathione reductase (GR) in Wistar rats. It also enhanced the level of LPO. The pretreatment of *P. Emblica* for 7 repeated days showed a profound pathological protection to liver cell as depicted by univacuolated hepatocytes. Pretreatment with *P. Emblica* at doses of 100 and 200 mg/kg b.w., prior to CCl₄ intoxication, showed significant reduction in the levels of AST, ALT, LDH, GST, LPO and DNA synthesis [105]. DHC-1, a standardized polyherbal formulation, showed hepatoprotective activity against CCl₄ induced liver damage. *P. emblica* is one of the components of this formulation along with *Bacopa monnieri*, Glycyrrhiza glabra, Mangifera indica and Syzygium aromaticum [106].

d. Protective effect of *P. emblica* against anti-TB drugs
Many biochemical manifestations of anti-TB drugs such as rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) induced hepatotoxicity either alone or in combination. Fifty per cent hydroalcoholic extract of the fruits of *P. emblica* was evaluated for their hepatoprotective activity against anti-TB drugs-induced hepatic injury. The result showed significant protection of liver against these drugs [107].

e. Protective effect of *P. emblica* against Fluoride
Increased fluoride exposure leads to fluorsis and further proceeds to damage the cardiovascular system. Fluoride is toxic to almost all the systems and causes oxidative stress in various tissues. Its ingestion also results in hyperlipemia and LPO. Exposure to fluoride resulted in significant elevation of plasma and hepatic lipid levels, bile acid content and reduced plasma HDL-C levels and hepatic HMG-CoA reductase (HMGR) activity. Administration of *P. emblica* fruit powder (2.5, 5 and 10 gm%) through diet significantly reduced plasma and hepatic lipid levels, tissue LPO and increased plasma HDL-C and fecal cholesterol levels in rats. Both hepatic HMGR activity and the bile acid (hepatic and fecal) production increased on administration of *P. emblica* fruit powder [108].

f. Protective effect of *P. emblica* against Nicotine
Nicotine is a potent parasympathomimetic alkaloid; it is first metabolized in the liver and induces lung and liver damages. Toxicity was induced by oral administration of nicotine at a dose of 5 mg/kg b.w. for 32 days in rats which caused significant decrease in the levels of SOD, CAT, total GSH and GPx in plasma, lung, liver, kidney and brain. The levels of SOD, CAT, GSH and GPx increased on administration of fruit extract of *P. emblica* (at 250 & 500 mg/kg b.w.) for 7 days. The protective effect was found to be dose dependent [109].

g. Protective effect of *P. emblica* against N-nitrosodimethylamine
*P. emblica* at a dose of 100 mg/kg b.w. in N-nitrosodimethylamine-treated rat liver reduced the expression of NOS and CYP2E1 protein, improve manganese SOD and CAT expression as well as supplementation offsets induced liver
injury via its antioxidant, anti-inflammation, anti-apoptosis, and antiautophagy properties [110]. Administration of aqueous extract of \textit{P. embilica} at the dose of 2 mg/day for 45 days decreased the level of LPO through its free radical scavenging activity and thus reduced the production of hydroxyl, peroxides and superoxide radicals and subsequently increased the concentration of GSH [111].

**h. Protective effect of \textit{P. embilica} against tert-butyl hydroperoxide (t-BHP)**

The aqueous and methanolic extracts of leaves and stem of \textit{P. embilica} were screened for hepatoprotective activity at a concentration of 50 µg/ml against t-BHP induced liver toxicity in HepG2 cells. Plant extracts showing hepatoprotective activity were assessed for their 50% effective concentration (EC\textsubscript{50}) values and their antioxidant activity using a DPPH assay. Methanolic extracts of \textit{P. embilica} showed significant hepatoprotective activity with EC\textsubscript{50} values of 19 µg/ml and 50% inhibitory concentration (IC\textsubscript{50}) of 3.38 µg/ml for DPPH scavenging activity against an IC\textsubscript{50} of 3.69 µg/ml for ascorbic acid [86].

**Hepatoprotective activities of \textit{Terminalia Chebula}**

\textit{T. chebula} is also called as "King of Medicines" because of its miraculous power of healing with a wide spectrum of biological activities. It has always been listed first in the Ayurvedic Medica. The fruit of \textit{T. chebula} is being used for the treatment of various diseases and disorders since ancient times. It is now considered as a precious source of unique natural products for development of medicines against various diseases and also for the development of industrial products. The phytochemical analysis showed that \textit{T. chebula} is a rich source of various phenolic and flavonoid compounds [112] (Table 4) which is well known for their free radical scavenging and iron chelating properties [113]. Seventy percent methanolic extract of \textit{T. chebula} has been reported to contain some notable antioxidants [114] (Table 4) and many bioactive constituents [115]. \textit{T. chebula} possesses a wide variety of scientifically tested biological activities like cytoprotective [116], spasmogenic [117], NF-kB inhibition in human lymphoblastic T cells [118], antioxidant, neuroprotective [119], antinociceptive [120], and antiulcerogenic [121] activities. It also showed antiplasmodial activity and cytotoxicity [122], hepato and nephrotoxicity [123], anti-artrhitic [124], anti-aging [125], anti-hyaluronidase effect [126], antacaries [127] and antidiabetic [128] activities.

**a. Protective effect of \textit{T. chebula} against paracetamol**

Paracetamol is a widely used analgesic and antipyretic drug and is safe when used in therapeutic doses. However, over dosage of paracetamol is known to be hepatotoxic and nephrotoxic in humans and in experimental animals. Treatment with \textit{T. chebula} leaf extract decreased the elevated serum levels of ALT, AST which may be a consequence of the stabilization of plasma membrane as well as repair of hepatic tissue damage caused by paracetamol [129].

**b. Protective effect of \textit{T. chebula} against CCl\textsubscript{4}**

Carbon tetrachloride increased the levels of serum markers like AST, ALT, ALP, \(\gamma\)-glutamate transpeptidase (GGTP), total bilirubin, total protein and LPO, indicating liver damage. However, treatment with \textit{T. chebula} ethanol:methanol fraction in 10:10 and 2:18 ratio remarkably recovered the decreased antioxidant levels and prevented CCl\textsubscript{4}-induced hepatotoxicity when compared to that of standard drug silymarin [130].

**c. Protective effect of \textit{T. chebula} against anti-TB drugs**

Administration of some anti-TB drugs such as rifampicin, isoniazid and pyrazinamide till 12 weeks caused hepatotoxicity. The 95% ethanolic extract of \textit{T. chebula} fruit showed hepatoprotective activity against anti-TB drug-induced toxicity which could be attributed to its prominent
antioxidative and membrane stabilizing activities \[131\].

d. Protective effect of *T. chebula* against 2-acetylamino-fluorene (2-AAF)

Effect of *T. chebula* extract was evaluated on 2-AAF-induced hepatocellular carcinoma in mice. At 25 mg/kg b.w., 2-AAF treatment showed liver injury and up-regulation of multidrug resistance-1 (MDR1) gene, generation of ROS and cyclooxygenase-2 (COX-2) expression via phosphorylation of Akt/PKB-MAPKs (Protein kinase B-mitogen activated protein kinase) and nuclear translocation of NF-κB. Pre-administration of 50 mg/kg b.w. of *T. Chebula* extract along with 25 mg/kg b.w. 2-AAF inhibited the expression of MDR1 by preventing ROS generation and COX-2 expression through Akt and MAPK signaling pathway. *T. chebula* may overcome the 2-AAF induced oxidative stress and drug resistance in the hepatic tissue of mice and prevent the possible neoplastic transformation leading to hepatocarcinoma \[132\].

e. Protective effect of *T. chebula* against Gentamicin

Gentamicin, an aminoglycoside is one of the most broadly used antibiotics. The clinical use of aminoglycosides is limited because of the development of toxic side effects such as hepatotoxicity, nephrotoxicity, ototoxicity etc. at a dose of 80 mg/kg b.w. once daily for seven days. Gentamicin produced significant elevation of serum biochemical parameters like ALT, AST with significant reduction in the level of total protein and albumin. Administration of aqueous extract of *T. chebula* significantly restored these parameters. The stabilization of these enzyme levels by the crude extract of *T. chebula* and the standard drug silymarin indicated the improvement of functional status of liver \[133\].

f. Protective effect of *T. chebula* against Iron toxicity

As iron is an essential element in the body, iron overloaded situation is coupled with the oxidative stress induced health problems including anemia, heart failure, liver cirrhosis, fibrosis, gallbladder disorders, diabetes, arthritis, depression, impotence, infertility and cancer \[134\]. Hepatic injury by iron results in the leakage of cellular enzymes into the bloodstream, resulting in augmented levels of serum ALT, AST, ALP and bilirubin. Overloaded iron causes significant increase of hydroxyproline, a marker biomolecule of liver fibrosis. The phytochemical analysis shows that *T. chebula* is a rich source of various phenolic and flavonoid compounds (Table 4) which are well known for their free radical scavenging and iron chelating properties \[135\]. The significant dose-dependent reduction in the formation of Fe\(^{2+}\) dependent hydroxyl radical in presence of *T. chebula* extract (methanolic) reveal its excellent iron chelating capacity. The *in vivo* experiments showed that methanolic fruit extract of *T. chebula* administration in iron overloaded mice significantly restored the antioxidant enzyme levels \[136\]. High level of hydroxyproline content in mice induced hepatic fibrosis. Treatment with methanolic fruit extract of *T. chebula* significantly reduced hydroxyproline content in iron intoxicated mice, thus demonstrating the hepatic fibrosis inhibitory potency of the fruit extract \[136\].

Protective effects of *T. chebula* fruit extract (aqueous) on the t-BHP induced oxidative injury was observed in cultured rat primary hepatocytes and rat liver \[137,138\].

Hepatoprotective activities of *T. bellerica*

*T. bellerica* Roxb, one the most essential constituent of Triphala, belongs to family Combretaceace. It is a large deciduous tree generally known as felleric mycobalane and locally as baheda which is found throughout central Asia and some other parts of the world. *T. bellerica* is used in treating hepatotoxicity due a presence of a lot of phytoconstituents \[139,140\] and flavons \[141\] (Table 4). Methanolic
extract of leaves, stem bark and fruit pulp of T. bellerica contains high content of phenolics and flavonoids [142]. Ethanolic leaf extracts of T. bellerica and P. amarus exhibited strong and effective in vitro antioxidant activity by chelating metal ions as well as scavenging free radicals [143]. Alcoholic fruits extract of T. bellerica has been reported to possess antiasthmatic [144], hepatoprotective [145] and antisympetidical [146], antistress [147], hypoglycemic [148], amoebicidal [149], antimicrobial [150] and antifungal properties against the pathogenic yeast, candida albicans and dermatophytes [151]. Its antihypertensive [152], hypolipidemic [153] and antioxidant activities [154] has also been reported.

a. Protective effect of T. bellerica against ethanol
Administration of ethanol results in significant elevation of serum marker enzymes AST, ALT, ALP and total bilirubin levels, while albumin and total protein were found to be decreased as compared to control group. Pretreatment with alcoholic and aqueous extract of T. bellerica significantly prevented the physical and biochemical changes induced by elevated level of above serum enzymes when compared with standard drug silymarin. The results showed that hepatoprotective activity of extracts were in the order; alcoholic extract (400 mg/kg, p.o.) > Silymarin (50 mg/kg, p.o.) > aqueous extract (400 mg/kg p.o.). From above study it can be concluded that T. bellerica fruit extracts possess a protective effect against ethanol-induced hepatotoxicity in Wistar rats, as evidenced by the physical, biochemical and histological parameters. [155].

b. Protective effect of T. bellerica against CCl4
Plasma levels of cholesterol and triglycerides increased significantly after CCl4 treatment [156]. Administration of aqueous fruit extract of T. bellerica significantly reduced plasma levels of cholesterol and triglycerides in rats [157]. Gallic acid (active principle of T. bellerica) was found effective against CCl4 induced liver and kidney damage [158]. Treatment with fruit extract of T. bellerica at different concentrations (200, 400 and 800 mg/kg b.w.) and standard gallic acid (at 50, 100 and 200 mg/kg b.w.) showed dose-dependent recovery in biochemical parameters such as AST, ALT, GSH, lipid peroxidase (LPx) but the effect was more pronounced with gallic acid[159].

c. Protective effect of T. bellerica against iron toxicity
High content of polyphenols and flavonoids of T. bellerica are responsible for its iron chelating activity. Methanolic extract of T. bellerica fruit can reduce the toxic level of iron in iron overloaded mice and hence protect liver from oxidative stress and fibrosis. Serum enzyme and ferritin levels, both indicators of severe iron overload, are also effectively lowered owing to its administration [160].

CONCLUSION
Triphala and its constituents show valuable hepatoprotective activity. Extracts of Triphala and different plant parts of P. embilica, T. chebula and T. bellerica showed significant protection against acute liver toxicity induced by high doses of drugs and chemicals, which might be due to high levels of phenolic and polyphenolic compounds in these plants. However, more in vitro studies will be beneficial to further understand the mechanism of action of these plants as an antioxidant and hepatoprotective agent. In view of the development of methods for antioxidative and hepatoprotective evaluation, there is immense need to standardize the in vitro and in vivo methods. All the constituents of Triphala provide significant prevention and treatment against various diseases. In comparison to P. embilica and T. bellerica, very little information is reported about hepatoprotective activity of T. bellerica plant and its parts. Further evaluation of T. bellerica needs to be carried out in order to explore the undisclosed areas and their practical
clinical applications, which can be used for the welfare of the mankind. Plant extracts, their mixtures, isolates and concentrates with antioxidant effects and hepatoprotective agents have to meet all the requirements of human health safety.

Table 4: Important phytochemicals present in constituents of Triphala

<table>
<thead>
<tr>
<th>Phytochemical name</th>
<th>P. embilica</th>
<th>T. chebula</th>
<th>T. belerica</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-sitosterol</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Casurarinin</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Chebulagic acid</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Chebulinic acid</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Chebulanin</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Corilagin</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Ellagic acid</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Ellargic acid</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Ellagotannin</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emblicanin A</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Emblicanin B</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Ethyl gallate</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>3 ethylgallic acid</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gallic acid</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Galloyl glucose</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Gallo-tannic acid</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>7-hydroxy 3’4’ flavones</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Isostrictinin</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Neochebulinic acid</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>1-Ogalloyl-β-D-glucose</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1,6-di-O-galloyl-β-D-glucose</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3,6-di-O-galloyl-D-glucose</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Penta-O galloyl-β-D-glucose</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>3,4,6 tri-O-galloyl-β-D-glucose</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>2,3,4,6 tetra-O-galloyl-β-D-glucose</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>1,2,3,4,6 penta-Ogalloyl-β-D-glucose</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Phenyllembolin</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Terchebulin</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Termilignan</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Tetra-O-galloyl-β-D-glucose</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Thanni lignin</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Trigallayl glucose</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

Reference No. [78-80,112,139-141]

REFERENCES


54. Fromenty B and Pessayre D. Inhibition of mitochondrial β-oxidation as a mechanism
76. Sharma A and Sharma KK, Chemoprotective Role of Triphala Against 1,2-Dimethylhydrazine Dihydrochloride Induced Carcinogenic Damage to Mouse Liver. Ind J Clin Bioch. 2011; 26: 290-295.
77. Sabina EP, Rasool M, Vedi M, Geethanjali A. Protective properties of traditional herbal formulation triphala against D-Galactosamine induced hepatotoxicity in


130. Boominathan M. Comparative study on antimicrobial, hepatoprotective activity of Terminalia Chebula different fraction.


